Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Cytopenia 1Advanced Cancer 1

Interventions

Cyclophosphamide 1492Cisplatin 1413Paclitaxel 1316Radiotherapy 1261Carboplatin 1249Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700Etoposide 678pembrolizumab 677Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × IDO-1 inhibitor LY3381916 × Clear all
NCT03335540 2022-09-26

ADVISE

Bristol-Myers Squibb

Phase 1 Completed
20 enrolled

Advanced Cancer

NCT01822691 2016-01-18

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
15 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡